The Am Law 100 firm launches a dedicated group to guide companies shaping the future of health, wellness and human longevity.
Longevity has reached a new milestone, and it didn’t come from a lab or a startup pitch deck. When a major US law firm builds a dedicated practice around an emerging sector, it usually means one thing: that sector is no longer speculative.
ArentFox Schiff, an Am Law 100 firm, has announced the launch of its Longevity & Healthspan Industry Group, positioning itself as a legal partner for companies working to extend how long and how well we live [1].
It is the first time a firm of this size has carved out longevity as its own industry group. And while that may sound like an internal reshuffle, it reflects a deeper shift taking place across health, wellness, and investment.
For years, longevity sat in an awkward space – too scientific for consumer health, too lifestyle-focused for traditional medicine. Today, that middle ground is exactly where growth is happening.
People are tracking sleep, ordering at-home blood tests, using AI-powered health apps and visiting preventive care clinics long before they are “sick.” Investors are following close behind, funding companies that promise earlier insights, personalized care and longer healthspan.
Gayland O Hethcoat II, who heads the new organization, remarked that the longevity ecosystem serves as a bridge for stakeholders in healthcare, biotech, consumer wellness and technology.
“Companies in this space face a complex and evolving regulatory environment. Our goal is to serve as a strategic legal partner to innovators building the next generation of health, wellness, and human performance platforms,” he said [1]. Innovation is moving faster than the rulebook, and someone has to help translate between the two.
To a general audience, legal strategy might sound far removed from aging science. But for longevity companies, it can determine whether an idea survives contact with the real world. Think of regulation as the guardrails on a highway. Without them, traffic moves fast, but crashes are inevitable. With them, progress may feel slower, but it is far more sustainable.
Longevity businesses often operate across multiple lanes at once. A wearable device, for example, may collect health data (raising privacy questions), make wellness claims (triggering advertising rules) and integrate AI (inviting regulatory scrutiny). A longevity clinic might blend telehealth, diagnostics, supplements and personalized care – all governed by different laws.
ArentFox Schiff’s approach is to bring those pieces together under one roof, drawing from its health care, FDA, privacy and data security, patent, corporate and government relations teams.
From diagnostics to destination health
The firm’s longevity group serves a wide range of players: biotech and life sciences companies, digital health and AI platforms, wearable tech makers, nutrition and supplement brands, fitness and recovery companies, longevity clinics and even medical travel and wellness tourism operators.
That breadth mirrors how longevity shows up in everyday life. It is not one product or pill; it is an entire ecosystem. A person might monitor biomarkers, adjust nutrition, optimize recovery and seek preventive imaging, all while generating streams of data and engaging with multiple providers. For companies building in this space, the challenge is making sure innovation does not outpace compliance.
ArentFox Schiff Chairman Anthony V Lupo framed the launch as both a response to client demand and a forward-looking bet.
“As the first Am Law 100 firm to establish longevity as a dedicated industry group, this launch reinforces our focus on staying ahead of the trends shaping our clients’ businesses,” he said [1]. The group, he added, supports clients “from stem cells to advances in reverse aging – helping them move bold ideas forward while managing risk.”
That phrase, managing risk, is key. As longevity attracts more capital, scrutiny will follow. Claims must be defensible. Data must be protected. Business models must hold up under regulation.
The move signals that longevity is entering a more disciplined phase. Dedicated legal infrastructure typically appears once a market reaches scale. It suggests to investors that exits, mergers and long-term value creation are no longer hypothetica.
For consumers, it may mean clearer standards and more accountability. As longevity products move into the mainstream, the difference between credible innovation and hype becomes harder to ignore.
Longevity is a human story. The desire to stay healthy, capable and independent for as long as possible. But turning that aspiration into an industry requires more than optimism. It requires structure.
By launching a dedicated Longevity & Healthspan Industry Group, ArentFox Schiff is acknowledging what many in the field already know: longevity is no longer a side conversation. It is becoming a defining pillar of how health is measured, delivered and financed. And like aging itself, it is entering a new phase. More complex, more accountable and very much here to stay.
[1] https://www.afslaw.com/perspectives/press-releases/arentfox-schiff-launches-first-its-kind-longevity-healthspan-industry
